ACC 2017 : Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin

Published: 03 Apr 2017

  • Views:

    Views Icon 531
  • Likes:

    Heart Icon 0


RE-CIRCUIT - Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation.

“At the American College of Cardiology congress, held in Washington D.C. in March this year, Dr Hugh Calkins (Professor of Cardiology and Director of the Electrophysiology Laboratory and Arrhythmia Service at the Johns Hopkins Hospital) presented the findings from Boehringer Ingelheim’s RE-CIRCUIT trail which aimed to illustrate the benefits of uninterrupted dabigatran etexilate in comparison to uninterrupted warfarin in pulmonary vein ablation.

Dr. Hugh Calkins is an internationally recognized expert on catheter ablation, atrial fibrillation, syncope, arrhythmogenic right ventricular dysplasia (ARVD) and arrhythmia management.

Dr. Calkins attended Williams College and Harvard Medical School before training in medicine at Massachusetts General Hospital. He received his cardiology training at Johns Hopkins. His first faculty position was at the University of Michigan, where he directed the Pacemaker Service, and he returned to Johns Hopkins as director of the Arrhythmia Service in 1992

Dr. Calkins is a former member of the American Board of Internal Medicine Electrophysiology Boards Test Writing Committee. Dr. Calkins is a fellow of the American College of Cardiology, the American Heart Association and the Heart Rhythm Society. Dr Calkins is a past president of the Heart Rhythm Society.”